Cargando…
Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment
At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based combinations that are being explored in late-stage clinical trials....
Autores principales: | Rubin, Krista M., Olszanski, Anthony J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857323/ https://www.ncbi.nlm.nih.gov/pubmed/33598316 http://dx.doi.org/10.6004/jadpro.2020.11.3.3 |
Ejemplares similares
-
Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes
por: Viereck, Amanda M., et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events
por: Kottschade, Lisa
Publicado: (2021) -
Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020) -
Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018) -
Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)